Periventricular and Intraventricular Haemorrhage

Last updated: April 1, 2026

Periventricular haemorrhage (PVH) is bleeding into the germinal matrix capillary bed – the tissue surrounding the lateral ventricles. It is common in preterm neonates (< 32 weeks gestation), very low birth weight neonates (< 1500 g), and is closely associated with hypoxic-ischaemic encephalopathy (HIE)

Intraventricular haemorrhage (IVH) occurs when bleeding extends into the ventricles.

Periventricular hemorrhagic infarction (PVHI) occurs when bleeding extends into the brain parenchyma.

Definition of terms

TermDefinition
Germinal matrixImmature tissue containing glial cells. It is immature, very friable, highly metabolic, and heavily reliant on oxygen.

Antenatal steroids (gexamethasone) greatly reduce the risk of future development of IVH/PVH. Preterm infants should be screened for IVH/PVH through cranial ultrasound. MRI can be ordered to determine the extent of the damage.

Factors associated with PVH/IVH and their treatment/prevention

Contributing factorTreatment/Prevention
PrematurityAntenatal steroids, supportive care
Perinatal asphyxia or HIEResuscitation, Supportive care
Neonatal seizuresPhenobarbital, EEG monitor
HypertensionAvoid rapid volume expansion
ShockFluid replacement, monitor U/O
Hypercarbia/hypoxiaAdequate oxygenation
Metabolic acidosisBicarbonate as per the neonatologist
AnaemiaBlood products as needed
CoagulopathyFFP
Rapid volume expansion (iatrogenic)Avoid rapid volume expansion
HydrocephalusAcetazolamide, neurosurgery

Classification of intraventricular hemorrhage (Papile)

GradeExtent of hemorrhage
Grade IGerminal matrix onlyGood
Grade IIIVH < 50%, no dilationGood
Grade IIIIVH > 50% and ventricular dilationMortality <10%. 30-40% have cognitive or motor deficits (blindness or Cerebral Palsy)
Grade IV (PVHI)Parenchymal haemorrhageMortality of 80%. 90% will have cognitive or motor deficits.
  • Risk factors
    • Maternal
      • Lack of antenatal steroids
      • Chorioamnionitis
      • Maternal bleeding
      • Vaginal delivery
      • Maternal hypertension
        • Hypertension→ elevated blood pressure in the neonate, causing bleeding in the germinal matrix
      • Vacuum delivery
    • Neonatal
  • Pathophysiology of IVH
    • Immature and fragile vessels in the germinal matrix: there is poorly developed structural support of blood vessels (immature basal lamina, few pericytes, and decreased glial fibers). Blood vessels are simple, endothelial-lined, and larger than mature capillaries. These capillaries are prone to hemorrhage.
    • Impaired cerebral autoregulation: blood pressure fluctuations (hypotension, hypertension, or rapid volume expansion) can lead to sudden changes in cerebral perfusion, increasing the risk of vessel rupture
    • Hypoxia-ischemic and reperfusion injury: Hypoxia or ichemia leads to anaerobic metabolism, energy failure, and endothelial injury. When blood flow is restored, reperfusion can trigger oxidative stress and free radical formation, weakening vessel integrity
    • Fluctuations in cerebral perfusion: neonatal conditions (such as RDS and PDA), mechanical ventilation, or rapid fluid administration cause fluctuations in cerebral perfusion pressure. These changes increase the risk of hemorrhage into the germinal matrix and ventricles
    • Coagulopathy and platelet dysfunction: preterm infants have immature coagulation systems (with decreased clotting factors) and platelet dysfunction. This exacerbates bleeding and limits clot formation after vessels have ruptured
    • Hemorrhage expansion and ventricular dilatation: bleeding can extend into the lateral ventricles (grade II – IV). Blood may clot, obstructing CSF drainage, which could lead to post-hemorrhage hydrocephalus. Blood breakdown products (e.g., hemosiderin) may trigger inflammation and fibrosis, further impairing CSF reabsorption at the arachnoid granulations.
  • Signs and symptoms
    • Early symptoms consistent with anemia: pallor and poor capillary refill
    • Hypotonia
    • Apnea
    • Respiratory distress
    • Seizures
    • Shock
    • Hydrocephalus
      • Monitor head circumference
  • Investigations
    • Cranial ultrasound: This is the best initial test. It can be used to screen neonates born at ≤ 30 weeks of gestation:
      • At day 7 – 10
      • At 4 – 6 weeks of age
      • Before discharge
    • MRI for complications
    • Complete blood count
    • RBS for hypoglycemia
    • Arterial blood gas analysis for metabolic acidosis
    • Coagulation profile
  • Treatment
    • NICU care
    • Umbilical artery catheter placement with X-ray confirmation
    • Correct metabolic and fluid disturbances
    • Maintain oxygenation and blood pressure
    • Treat seizures, anaemia, and coagulopathy
    • Indomethacin may be given to reduce the risk of severe IVH
    • Surgical treatment of hydrocephalus
    • Long-term follow-up
  • Prevention
    • Antenatal
      • Corticosteroids
      • Early transfer
    • Perinatal
      • Delayed cord clamping (30 – 180 seconds)
    • Postnatal
      • Midline head position
      • Minimal handling
      • Avoid suctioning
      • Stable blood pressure and oxygenation
      • Avoid rapid fluids
  • Long-term complications of IVH
    • Cerebral palsy
    • Post-hemorrhagic ventricular dilatation (PHVD) → Hydrocephalus
    • Periventricular leukomalacia (PVL)
      • Permanent parenchymal damage is characterized by the presence of periventricular cysts.
      • This has a tendency to affect the lower limb and optic nerve fibers the most.
    • Seizures
    • Developmental delay

Reference Intervals
Biochemistry
ACTHP: <80 ng/L
ALTP: 5–35 U/L
AlbuminP: 35–50 g/L
AldosteroneP: 100–500 pmol/L
Alk. phosphataseP: 30–130 U/L
α-AmylaseP: 0–180 IU/dL
α-FetoproteinS: <10 kU/L
Angiotensin IIP: 5–35 pmol/L
ADHP: 0.9–4.6 pmol/L
ASTP: 5–35 U/L
BicarbonateP: 24–30 mmol/L
BilirubinP: 3–17 μmol/L
BNPP: <50 ng/L
CRPP: <10 mg/L
CalcitoninP: <0.1 mcg/L
Calcium (ionized)P: 1.0–1.25 mmol/L
Calcium (total)P: 2.12–2.60 mmol/L
ChlorideP: 95–105 mmol/L
CholesterolP: <5.0 mmol/L
VLDLP: 0.128–0.645 mmol/L
LDLP: <2.0 mmol/L
HDLP: 0.9–1.93 mmol/L
Cortisol AMP: 450–700 nmol/L
Cortisol MidnightP: 80–280 nmol/L
CK ♂P: 25–195 U/L
CK ♀P: 25–170 U/L
CreatinineP: 70–100 μmol/L
FerritinP: 12–200 mcg/L
FolateS: 2.1 mcg/L
FSHP: 2–8 U/L ♂; >25 menopause
GGT ♂P: 11–51 U/L
GGT ♀P: 7–33 U/L
Glucose (fasting)P: 3.5–5.5 mmol/L
Growth hormoneP: <20 mu/L
HbA1C (DCCT)B: 4–6%
HbA1C (IFCC)B: 20–42 mmol/mol
Iron ♂S: 14–31 μmol/L
Iron ♀S: 11–30 μmol/L
Lactate (venous)P: 0.6–2.4 mmol/L
Lactate (arterial)P: 0.6–1.8 mmol/L
LDHP: 70–250 U/L
LHP: 3–16 U/L
MagnesiumP: 0.75–1.05 mmol/L
OsmolalityP: 278–305 mosmol/kg
PTHP: 0.8–8.5 pmol/L
PotassiumP: 3.5–5.3 mmol/L
Prolactin ♂P: <450 U/L
Prolactin ♀P: <600 U/L
PSAP: 0–4 mcg/mL
Protein (total)P: 60–80 g/L
Red cell folateB: 0.36–1.44 μmol/L
Renin (erect)P: 2.8–4.5 pmol/mL/h
Renin (recumbent)P: 1.1–2.7 pmol/mL/h
SodiumP: 135–145 mmol/L
TBGP: 7–17 mg/L
TSHP: 0.5–4.2 mU/L
T4P: 70–140 nmol/L
Free T4P: 9–22 pmol/L
TIBCS: 54–75 μmol/L
TriglyceridesP: 0.50–2.3 mmol/L
T3P: 1.2–3.0 nmol/L
Troponin TP: <0.1 mcg/L
Urate ♂P: 210–480 μmol/L
Urate ♀P: 150–390 μmol/L
UreaP: 2.5–6.7 mmol/L
Vitamin B12S: 0.13–0.68 nmol/L
Vitamin DS: 50 nmol/L
Arterial Blood Gases
pH7.35–7.45
PaCO₂4.7–6.0 kPa
PaO₂>10.6 kPa
Base excess±2 mmol/L
Urine
Cortisol (free)<280 nmol/24h
Hydroxyindole acetic acid16–73 μmol/24h
Hydroxymethylmandelic acid16–48 μmol/24h
Metanephrines0.03–0.69 μmol/mmol cr.
Osmolality350–1000 mosmol/kg
17-Oxogenic steroids ♂28–30 μmol/24h
17-Oxogenic steroids ♀21–66 μmol/24h
17-Oxosteroids ♂17–76 μmol/24h
17-Oxosteroids ♀14–59 μmol/24h
Phosphate (inorganic)15–50 mmol/24h
Potassium14–120 mmol/24h
Protein<150 mg/24h
Protein/creatinine ratio<3 mg/mmol
Sodium100–250 mmol/24h
Haematology
WCC4.0–11.0 ×10⁹/L
RBC ♂4.5–6.5 ×10¹²/L
RBC ♀3.9–5.6 ×10¹²/L
Hb ♂130–180 g/L
Hb ♀115–160 g/L
PCV ♂0.4–0.54 L/L
PCV ♀0.37–0.47 L/L
MCV76–96 fL
MCH27–32 pg
MCHC300–360 g/L
RDW11.6–14.6%
Neutrophils2.0–7.5 ×10⁹/L (40–75%)
Lymphocytes1.0–4.5 ×10⁹/L (20–45%)
Eosinophils0.04–0.44 ×10⁹/L (1–6%)
Basophils0–0.10 ×10⁹/L (0–1%)
Monocytes0.2–0.8 ×10⁹/L (2–10%)
Platelets150–400 ×10⁹/L
Reticulocytes0.8–2.0% / 25–100 ×10⁹/L
Prothrombin time10–14 s
APTT35–45 s
Paediatric
Pulse Rate (bpm)
Neonate140–160
Infant <1yr120–140
1–5 years110–130
5–12 years80–120
>12 years70–100
Respiratory Rate (tachypnoea)
0–2 months≥60/min
2–12 months≥50/min
1–5 years≥40/min
>5 years≥30/min
Blood Pressure (mmHg)
Term65/45
1 year75/50
4 years85/60
8 years95/65
10 years100/70
Weight Formulas
3–12 months(a + 9)/2 kg
1–6 years2a + 8 kg
>6 years(7a − 5)/2 kg
Haemoglobin (g/dL)
Term newborn13–20
1 month11–18
2 months10–15
1–2 years10–13
>2 years11–14
MUAC (6 months–5 years)
Obese>17.5 cm
Normal13.5–17.4 cm
At risk12.5–13.4 cm
Moderate malnutrition11.5–12.4 cm
Severe malnutrition<11.5 cm
Developmental Milestones
Social smile1.5 months
Head control4 months
Sits unsupported7 months
Crawls10 months
Stands unsupported10–12 months
Walks12–13 months
Talks18 months
CSF WBC (/mm³)
Term newborn0–25
>2 weeks0–5
Calculator

Post Discussion

Your email address will not be published. Required fields are marked *